Novel dual-targeted gastrin-releasing peptide receptor and fibroblast activation protein radiopharmaceuticals for molecular imaging of heterogeneous breast tumors.
OBJECTIVES The gastrin-releasing peptide receptor-targeted radioantagonist RM2 has shown promise for breast cancer imaging, but its limited metabolic stability may hamper in vivo performance. To improve stability and pharmacokinetics while addressing tumor heterogeneity, we developed two novel dual-targeted GRPR/fibrob...